Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Prostatic Neoplasms 3Neoplasms 2Lymphatic Metastasis 2Thyroid Nodule 1Social Isolation 1Rectal Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Pelvic Neoplasms 1Ovarian Neoplasms 1Neurobehavioral Manifestations 1Lung Neoplasms 1Disease 1Depression 1Communication 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

Carboplatin 345Cisplatin 240Paclitaxel 208Radiotherapy 206Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 146Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 101Etoposide 98Bevacizumab 96Specimen Handling 84Nivolumab 77durvalumab 73Radiosurgery 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 44Biopsy 43Irinotecan 42Radiation 41Topotecan 39Standard of Care 38Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Artificial Intelligence × Clear all
NCT07458425 2026-04-06

The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk

University of Illinois at Chicago

Phase NA Recruiting
400 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡